| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 03/21/2006 | US7014853 Family of immunoregulators designated leukocyte immunoglobulin-like receptors (LIR) |
| 03/21/2006 | US7014848 inducing an antigen-specific immune response by adminstering autologous allogeneic antigen-presenting cells |
| 03/21/2006 | US7014847 Methods for preventing reovirus recognition for the treatment of cellular proliferative disorders |
| 03/21/2006 | US7014838 Use of biomolecular targets in the treatment and visualization of brain tumors |
| 03/21/2006 | CA2443314C Method of imaging cell death in vivo |
| 03/21/2006 | CA2443214C Vaccine composition comprising human papilloma virus 16 l1 virus-like particle (hpv 16 l1 vlp), human papilloma virus 18 l1 virus-like particle (hpv 18 l1 vlp) and 3-de-o-acylatedmonphosphoryl lipid a (3d-mpl) and alum |
| 03/21/2006 | CA2182272C Modified papilloma virus l2 protein and vlps formed therefrom |
| 03/21/2006 | CA2154080C Novel anticoagulant cofactor activity |
| 03/16/2006 | WO2006029369A2 Methods and compositions for measuring natriuretic peptides and uses thereof |
| 03/16/2006 | WO2006029258A2 Aptamer medicinal chemistry |
| 03/16/2006 | WO2006029224A2 Methods of using death receptor ligands and cd20 antibodies |
| 03/16/2006 | WO2006029220A2 Combination therapy with anti-ctla4 and anti-4-1bb antibodies |
| 03/16/2006 | WO2006029219A2 Human monoclonal anti-ctla4 antibodies in cancer treatment |
| 03/16/2006 | WO2006029089A2 Tetrahydrocannabinoid- protein conjugates for the production of antibodies for the detection of tεtrahydrocannabinoid components in saliva |
| 03/16/2006 | WO2006028939A1 Controlled and directed local delivery of anti-inflammatory compositions |
| 03/16/2006 | WO2006028428A1 Antimicrobial aerococus viridans strain n°167k and a drug viabak based thereon |
| 03/16/2006 | WO2006028214A1 Vaccine for oral administration |
| 03/16/2006 | WO2006028197A1 Anti-a33 antibody |
| 03/16/2006 | WO2006027698A1 Decreasing potential iatrogenic risks associated with influenza vaccines |
| 03/16/2006 | WO2006027685A2 Glycosylceramide adjuvant for saccharide antigens |
| 03/16/2006 | WO2006027584A2 Vaccines against neisseria |
| 03/16/2006 | WO2006027468A2 Hla-dp4 restricted t cd4+ du vih epitopes and the use thereof |
| 03/16/2006 | WO2006027300A2 Carrier conjugates of gnrh-peptides |
| 03/16/2006 | WO2005121175A9 Env polypeptide complexes and methods of use |
| 03/16/2006 | WO2005121168A3 Heparin binding peptide |
| 03/16/2006 | WO2005118813A3 Nucleic acids, polypeptides, methods of expression, and immunogenic compositions associated with sars corona virus spike protein |
| 03/16/2006 | WO2005115453A3 Treatment of polychondritis and mononeuritis multiplex with anti-cd20 antibodies |
| 03/16/2006 | WO2005113003A3 Method for augmenting b cell depletion |
| 03/16/2006 | WO2005110013A3 Methods, compositions, and preparations for delivery of immune response modifiers |
| 03/16/2006 | WO2005108995A3 Compositions, test kits and methods for detecting helicobacter pylori |
| 03/16/2006 | WO2005106488A3 Diagnostics and therapeutics for diseases associated with g protein-coupled beta-2 adrenoceptor (adrb2) |
| 03/16/2006 | WO2005105845A3 Phep, an amino acid permease of staphylococcus aureus |
| 03/16/2006 | WO2005094891A3 Method for solubilising peptide mixtures |
| 03/16/2006 | WO2005091991A3 Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| 03/16/2006 | WO2005090994A3 Diagnostics and therapeutics for diseases associated with protein kinase, cgmp-dependent, type i (prkg1) |
| 03/16/2006 | WO2005090584A3 Influenza vaccine based on fowl plague viruses |
| 03/16/2006 | WO2005084410A9 Compositions and methods for topical application and transdermal delivery of botulinum toxins |
| 03/16/2006 | WO2005077007A3 Methods of diagnosing and treating pre-eclampsia or eclampsia |
| 03/16/2006 | WO2005063815A3 Fcϝ receptor-binding polypeptide variants and methods related thereto |
| 03/16/2006 | WO2005060998A3 Methods of modulating cytokine activity; related reagents |
| 03/16/2006 | WO2005044366A3 System and method for transdermal vaccine delivery |
| 03/16/2006 | WO2005023187A3 Inhibitor of cardiac tachyarrhythmias |
| 03/16/2006 | WO2005012337A3 Antigenic peptides of sars coronavirus and uses thereof |
| 03/16/2006 | WO2004033663A3 Carbohydrate-based synthetic vaccines for hiv |
| 03/16/2006 | US20060058736 Novel vaccine |
| 03/16/2006 | US20060058512 Process for producing humanized chimera antibody |
| 03/16/2006 | US20060058511 Method for stabilizing protein solution preparation |
| 03/16/2006 | US20060058505 Nucleic acid and polypeptide linked to breast cancer and uses therefor |
| 03/16/2006 | US20060058257 Influencing angiogenesis using CD66a |
| 03/16/2006 | US20060058251 Use of immunostimulatory nucleic acids containing unmethylated CpG dinucleotide sequences to treat viral infections; use with viral antigen in vaccine or without a viral antigen |
| 03/16/2006 | US20060058226 Gd3-mimetic peptides |
| 03/16/2006 | US20060058223 TAJ in neuronal function |
| 03/16/2006 | US20060058220 Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same |
| 03/16/2006 | US20060057700 Using glycosylated pilin as diagnostic indicator and preventative initation in treating pseudomonal infections; immunotherapy; glycosylated with the O-antigen; Pseudomonas aeruginosa; Escherichia coli |
| 03/16/2006 | US20060057699 Vaccines; mammalian nucleated cells and mammalian adherent cells that are stably infected with an Anaplasma species |
| 03/16/2006 | US20060057648 Diagnostics and therapeutics for diseases associated with neuromedin u1 receptor (nmu1) |
| 03/16/2006 | US20060057641 Having T cell stimulatory activity of a dog dander allergen, therapy |
| 03/16/2006 | US20060057632 Artificial antibody library with super-repertory |
| 03/16/2006 | US20060057620 Treatment of HIV infection |
| 03/16/2006 | US20060057574 Tissue specific expression |
| 03/16/2006 | US20060057208 Biocompatible drug delivery apparatus and methods |
| 03/16/2006 | US20060057166 Methods for treating Raynaud's syndrome |
| 03/16/2006 | US20060057165 Clostridium botulinum toxin formulation and method for reducing weight |
| 03/16/2006 | US20060057164 Isolated, purified polynucleotides, expression vector, host cells, antibodies; mutation functionally disrupting catalytic domain |
| 03/16/2006 | US20060057163 adjuvant compound chosen from the acrylic or methacrylic polymers and the copolymers of maleic anhydride and an alkenyl derivative especially with polyalkenyl ethers of sugars or polyalcohols; heterologus influenza protein |
| 03/16/2006 | US20060057162 Induction of cytotoxic T-lymphocyte responses |
| 03/16/2006 | US20060057161 Detection of coronavirus infection |
| 03/16/2006 | US20060057160 Vaccine composition |
| 03/16/2006 | US20060057159 Immunize cats, veterinary medicine |
| 03/16/2006 | US20060057158 Production of attenuated, human-bovine chimeric respiratory syncytial virus vaccines |
| 03/16/2006 | US20060057156 Materials and methods for inductions of immune tolerance |
| 03/16/2006 | US20060057155 Adp-ribosylating bacterial toxins |
| 03/16/2006 | US20060057154 Compositions for inducing of immunotolerance |
| 03/16/2006 | US20060057153 Method and composition for the inhibition of mitosis |
| 03/16/2006 | US20060057152 Helicobacter system and uses thereof |
| 03/16/2006 | US20060057151 BmpB novel nucleotide and amino acid sequences and diagnostic and therapeutic uses thereof |
| 03/16/2006 | US20060057150 Compositions against chicken coccidiosis |
| 03/16/2006 | US20060057149 Humanized antibodies against West Nile Virus and therapeutic and prophylactic uses thereof |
| 03/16/2006 | US20060057148 Compositions and methods for treatment of non-hodgkin's lymphoma |
| 03/16/2006 | US20060057147 Antibody recognizing antibody |
| 03/16/2006 | US20060057146 Selective targeting of tumor vasculature using antibody molecules |
| 03/16/2006 | US20060057145 Methods to prevent tumor recurrence by blockade of tgf-beta |
| 03/16/2006 | US20060057144 reducing IgG-mediated tissue damage and inflammation from rheumatoid arthritis; compound inhibits Fc.gamma.RIIa receptor binding of immunoglobulin; drug design; BRI6728, BRI6734, BRI6813, BRI6800, BRI6801, BRI6802, BRI6803, BRI6814, BRI6817, BRI6822, BRI6823, BRI6824, BRI6798, BRI6799, BRI6815, BRI6825 |
| 03/16/2006 | US20060057143 Diagnostics and therapeutics for diseases associated with chemokine receptor 11 (ccr11) |
| 03/16/2006 | US20060057142 Biocompatible devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood |
| 03/16/2006 | US20060057141 Ovarian carcinoma polypeptides having a specific amino acid sequence, its fusion proteins and polynucleotides encoding them; cancer vaccines |
| 03/16/2006 | US20060057140 Anticoagulant agents useful in treatment of thrombosis |
| 03/16/2006 | US20060057139 Process for producing humanized chimera antibody |
| 03/16/2006 | US20060057138 Protein that includes a heavy chain immunoglobulin variable domain sequence and a light chain immunoglobulin variable domain sequence; the protein ligand binds to Tie1 ectodomain, a receptor tyrosine kinase protein that includes a transmembrane domain; use in modulating angiogenesis |
| 03/16/2006 | US20060057137 Glp-1 and methods for treating diabetes |
| 03/16/2006 | US20060057136 Immunotherapy of B-Cell malignancies using anti-CD22 antibodies |
| 03/16/2006 | US20060057135 Mucosal vascular addressins and uses thereof |
| 03/16/2006 | US20060057134 Antibody against antibacterial peptide and utiliazation thereof |
| 03/16/2006 | US20060057130 An isolated RNA-pulsed antigen presenting cell comprising tumor specific RNA; stimulation of cytotoxic T-lymphocyte proliferation ex vivo or in vivo for adoptive immunotherapy; anticarcinogenic agents; antitumor agents; bactericides; viricides |
| 03/16/2006 | US20060057120 Administration of dendritic cells partially matured in vitro for the treatment of tumors |
| 03/16/2006 | US20060057116 Recombinant influenza viruses for vaccines and gene therapy |
| 03/16/2006 | US20060057115 Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof |
| 03/16/2006 | US20060057112 Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances and uses thereof |
| 03/16/2006 | US20060057110 Antigen-presenting cells for neuroprotection and nerve regeneration |
| 03/16/2006 | US20060057108 Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment |